| Preview | Issue Date | Title / Name | Author(s) |
| Sep-2020 | Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in | Nowak, A.K.; Lesterhuis, W.J.; Cook, A.M.; Kok, P.S.; Brown, C.; Langford, A.; Yip, S.; Stockler, M.R.; Hughes, B.G.; Karikios, D.J.; John, T.; Kao, S.C.H.; Leslie, C.; Pavlakis, N.; Briscoe, Karen; O'Byrne, K.J.; Karapetis, C.S.; Lam, W.S.; Briscoe, Karen | |
| Aug-2023 | First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: Checkmate 401 | Dummer, R.; Corrie, P; Gutzmer, R.; Meniaway, T. M.; Del Vecchio, M.; Lebbe, C; Guida, M.; Dutriaux, C.; Dreno, B.; Meyer, N.; Ferrucci, P. F.; Dalle, S.; Khattak, M. A.; Grob, J.-J.; Briscoe, K.; Larkin, J.; Mansard, S.; Lesimple, T.; Guidoboni, M.; Sabatini, S.; Richtig, E.; Herbst, R.; Lobo, M.; Askelson, M.; Ascierto, P. A.; Maio, M.; Briscoe, Karen | |
| Jul-2021 | Immunotherapy-related gastritis: Two case reports and literature review | Woodford, R.; Briscoe, K.; Tustin, R.; Jain, A.; Briscoe, Karen; Tustin, Richard; Jain, Ankit | |
| Jul-2016 | Melanoma and immunotherapy bridge 2015: Naples, Italy. 1-5 December 2015. | Nanda, V.G.Y.; Peng, W.; Hwu, P.; Davies, M.A.; Ciliberto, G.; Fattore, L.; Malpicci, D.; Aurisicchio, L.; Ascierto, P.A.; Croce, C.M.; Mancini, R.; Spranger, S.; Gajewski, T.F.; Wang, Y.; Ferrone, S.; Vanpouille-Box, C.; Wennerberg, E.; Pilones, K.A.; Formenti, S.C.; ...; Hirsh, V.; Briscoe, Karen | |
| Aug-2021 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG) | Siu, H. W. D.; Tebbutt, N.; Chantrill, L.; Karapetis, C.; Steer, C.; Wilson, K.; Espinoza, D.; Bailey, L.; Yip, S.; Cuff, J.; Pavlakis, N.; Thavaneswaran, S.; Briscoe, K.; Srivastav, R.; Shannon, J.; Segelov, E.; Tie, J.; Caird, S.; Francesconi, A.; Price, T.; Wuttke, M.; Ladwa, R.; Sjoquist, K.; Burge, M.; Briscoe, Karen | |
| Dec-2024 | Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting - Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial | Grimison, P.; Mersiades, A.; Kirby, A.; Morton, R.L.; Walsh, A.; Lee, Y.; Simes, R.J.; Stockler, M.R.; Tognela, A.; Olver, I.; Haber, P.; Abdi, E.; Della-Fiorentina, S.; Aghmesheh, M.; Fox, P.; Briscoe, Karen; Sanmugarajah, J.; Marx, G.; Kichenadasse, G.; Wheeler, H.; Chan, M.; Shannon, J.; Gedye, C.; Begbie, Stephen; Briscoe, Karen; Begbie, Stephen | |
| Nov-2020 | Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. | Grimison, P.; Mersiades, A.; Kirby, A.; Lintzeris, N.; Morton, R.; Haber, P.; Olver, I.; Walsh, A.; McGregor, I.; Cheung, Y.; Tognela, A.; Hahn, C.; Briscoe, Karen; Aghmesheh, M.; Fox, P.; Abdi, E.; Clarke, S.; Della-Fiorentina, S.; Shannon, J.; Gedye, C.; Begbie, Stephen; Simes, J.; Stockler, M.; Briscoe, Karen; Begbie, Stephen | |
| Sep-2023 | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial | Friedlander, M.; Mileshkin, L.; Lombard, J.; Frentzas, S.; Gao, B.; Wilson, M.; Meniawy, T.; Baron-Hay, S.; Briscoe, K.; McCarthy, N.; Fountzilas, C.; Cervantes, A.; Ge, R.; Wu, J.; Spira, A.; Briscoe, Karen | |
| Nov-2015 | A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial | Davidson, A; Veillard, A-S; Tognela, A.; Chan, M. M. K.; Hughes, B. G. M.; Boyer, M.; Briscoe, K.; Begbie, S.; Abdi, E.; Crombie, C.; Long, J.; Boyce, A.; Lewis, C. R.; Varma, S.; Broad, A.; Muljadi, M.; Chinchen, S.; Espinoza, D.; Coskinas, X.; Pavlakis, N.; Millward, M.; Stockler, M. R.; Australasian Lung cancer Trials Group ALTG; Briscoe, Karen; Begbie, Stephen | |
| Oct-2015 | Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy. | Nayar, Namrata; Briscoe, Karen; Nayar, Namrata; Briscoe, Karen | |
| Apr-2016 | Toxic Epidermal Necrolysis-like Reaction with Severe Satellite Cell Necrosis Associated with Nivolumab in a Patient with Ipilimumab Refractory Metastatic Melanoma. | Nayar, Namrata; Briscoe, Karen; Fernandez, Penas P.; Nayar, Namrata; Briscoe, Karen | |
